https://doi.org/10.4081/monaldi.2022.2254
The impact of anemia on the mortality of COPD patients hospitalized for acute exacerbation resulting in respiratory failure
Submitted: March 2, 2022
Accepted: August 4, 2022
Published: August 9, 2022
Accepted: August 4, 2022
Abstract Views: 1158
PDF: 338
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Anemia increases mortality in patients with chronic obstructive pulmonary disease (COPD), but its effects on mortality and survival time for different levels of airflow limitation severity are unclear. Our goal was to investigate the effects of anemia on survival time and mortality in COPD patients with varying degrees of airflow limitation. We looked at 300 consecutive COPD patients in the past. Their demographic information, Charlson comorbidity index, previous early (30 days) and late (>30 days) hospitalizations, blood counts, and post-bronchodilator spirometric values were all recorded. They were contacted by phone to check on their vital status, and their mortality rates were calculated. Anemic patients had a mean overall survival time of 31.9 2.8 months and normal patients had a mean overall survival time of 41.7 2.1 months (p=0.001). Their 1-year and 2-year mortality rates are higher. Age, Charlson comorbidity index, BMI, FEV1%, anemia, MCV, hemoglobin, serum creatinin, and early and late hospitalizations all had an impact on mortality. BMI, anemia, and FEV1% remained risk factors for death. Anemic group 2 patients had a higher mortality rate than groups 3 and 4. Anemic patients in groups 2 and 4 had shorter survival times. Anemic COPD patients have higher 1-year and 2-year mortality rates. Mortality is affected by age, Charlson comorbidity index, BMI, FEV1%, anemia, MCV, hemoglobin, serum creatinin, and early and late hospitalizations. BMI, anemia, and FEV1% remained risk factors for death. Anemic group 2 patients have a higher mortality rate than groups 3 and 4. Anemic patients in groups 2 and 4 have shorter survival times.
Sarkar M, Rajta PN, Khatana J. Anemia in chronic obstructive pulmonary disease: Prevalence, pathogenesis, and potential impact. Lung India 2015;32:142-51.
DOI: https://doi.org/10.4103/0970-2113.152626
Global initiative for chronic obstructive lung disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease [updated 2022]. Accessed Jan 11 2022. Available from: www.goldcopd.org
Weiss G, Goodnough LT. Anemia of chronic disease. N Eng J Med 2005;352:1011-23.
DOI: https://doi.org/10.1056/NEJMra041809
Celli BR, Cote CG, Lareau SC, et al. Predictors of survival in COPD: More than just the FEV1. J Respir Med 2008;102:27-35.
DOI: https://doi.org/10.1016/S0954-6111(08)70005-2
Chambellan A, Chailleux E, Similowski T, ANTADIR Observatory Group. Prognostic value of the hematocrit in patients with severe COPD receiving long-term oxygen therapy. Chest 2005;128:1201-8.
DOI: https://doi.org/10.1378/chest.128.3.1201
Similowski T, Agustí A, MacNee W, et al. The potential impact of anaemia of chronic disease in COPD. Eur Resp J 2006;27:390-6.
DOI: https://doi.org/10.1183/09031936.06.00143704
Halpern MT, Zilberberg MD, Schmier JK, et al. Anemia, costs, and mortality in chronic obstructive pulmonary disease. Cost Eff Resour Alloc 2006;4:17.
DOI: https://doi.org/10.1186/1478-7547-4-17
Cote C, Zilberberg MD, Mody SH, et al. Haemoglobin level and its clinical impact in a cohort of patients with COPD. Eur Respir J 2007;29:923-9.
DOI: https://doi.org/10.1183/09031936.00137106
Boutou A, Pitsiou G, Stanopoulos I, et al. Prevalence of anemia of chronic disease in patients with chronic obstructive pulmonary disease. Eur Resp J 2011;38:1026.
Pandey S, Garg R, Kant S, et al. Chronic obstructive pulmonary disease with anemia as comorbidity in north Indian population. Adv Biomed Res 2018;7:152.
DOI: https://doi.org/10.4103/abr.abr_128_18
World Health Organization. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. Accessed March 2, 2022 Available from: https://who.int/vmnis/indicators/haemoglobin.pdf
Putcha N, Fawzy A, Paul GG, et al. Anemia and adverse outcomes in a chronic obstructive pulmonary disease population with a high burden of comorbidities: an analysis from SPIROMICS. Ann Am Thorac Soc 2018;15:710-7.
DOI: https://doi.org/10.1513/AnnalsATS.201708-687OC
Divo M, Celli BR. Multimorbidity in patients with chronic obstructive pulmonary disease. Clin Chest Med 2020;41:405-19.
DOI: https://doi.org/10.1016/j.ccm.2020.06.002
K Yang, Y Wu, D Chen, et al. The impact of lung function on extra-pulmonary diseases and all-cause mortality in US adult population with and without COPD. Clin Epidemiol 2020;12:997-1005.
DOI: https://doi.org/10.2147/CLEP.S270599
Zavarreh RH, Zahmatkesh MM, Vakili M, et al. Association between anemia and COPD in Iranian population. Int J Hematol Oncol Stem Cell Res 2013;7:6–10.
Sharma RK, Chakrabarti S. Anaemia secondary to erythropoietin resistance: important predictor of adverse outcomes in chronic obstructive pulmonary disease. Postgrad Med J 2016;92:636-9.
DOI: https://doi.org/10.1136/postgradmedj-2015-133814
Haraguchi M, Nakamura H, Sasaki M, et al. Determinants of chronic obstructive pulmonary disease severity in the late-elderly differ from those in younger patients. BMC Res Notes 2016;9:7.
DOI: https://doi.org/10.1186/s13104-015-1810-8
Tanner H, Moschovitis G, Kuster GM, et al. The prevalence of anemia in chronic heart failure. Int J Cardiol 2002;86:115-21.
DOI: https://doi.org/10.1016/S0167-5273(02)00273-5
Cavaillès A, Brinchault-Rabin G, Dixmier A, et al. Comorbidities of COPD. Eur Respir Rev 2013;22:454-75.
DOI: https://doi.org/10.1183/09059180.00008612
Menou A, Pain M, Pivette J, et al.[ Importance des comorbidities dansl’anemie de la BPCO: impact medico - economique et survie a 3 ans].[Article in French with English Abstract]. Rev Malad Respir 2016;33:565-72.
DOI: https://doi.org/10.1016/j.rmr.2015.12.008
Barba R, de Casasola GG, Marco J, et al. Anemia in chronic obstructive pulmonary disease: a readmission prognosis factor. Curr Med Res Opin 2012;28:617-22.
DOI: https://doi.org/10.1185/03007995.2012.675318
Yu TC, Zhou H, Suh K, et al. Assessing the importance of predictors in unplanned hospital readmissions for chronic obstructive pulmonary disease. Clinicoecono Outcomes Res 2015;7:37-51.
DOI: https://doi.org/10.2147/CEOR.S74181
Boutou AK, Karrar S, Hopkinson NS, et al. Anemia, and survival in chronic obstructive pulmonary disease: a dichotomous rather than a continuous predictor. Respiration 2013;85:126-31.
DOI: https://doi.org/10.1159/000338792
Martinez-Rivera C, Portillo K, Muñoz-Ferrer A, et al. Anemia is a mortality predictor in hospitalized patients for COPD exacerbation. COPD 2012;9:243-50.
DOI: https://doi.org/10.3109/15412555.2011.647131
Kassim AA, Payne AB, Rodeghier M, et al. Low forced expiratory volume is associated with earlier death in sickle cell anemia. Blood 2015;126:1544-50.
DOI: https://doi.org/10.1182/blood-2015-05-644435
How to Cite
Cireli, Emel, and Aydan Mertoğlu. 2022. “The Impact of Anemia on the Mortality of COPD Patients Hospitalized for Acute Exacerbation Resulting in Respiratory Failure”. Monaldi Archives for Chest Disease 93 (2). https://doi.org/10.4081/monaldi.2022.2254.
Copyright (c) 2022 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Similar Articles
- Maryam Hassan, Akbar Shoukat Ali, Ali Bin Sarwar Zubairi, Zahra Ali Padhani, Salman Kirmani, Huzaifa Ahmad, Zafar Fatmi, Jai K Das, Gene polymorphisms and risk of idiopathic pulmonary fibrosis: a systematic review and meta-analysis , Monaldi Archives for Chest Disease: Early Access
- Maria Tamara Neves Pereira, Mariana Tinoco, Margarida Castro, Luísa Pinheiro, Filipa Cardoso, Lucy Calvo, Sílvia Ribeiro, Vitor Monteiro, Victor Sanfins, António Lourenço, Assessing cardiac resynchronization therapy response in heart failure patients: a comparative analysis of efficacy and outcomes between transvenous and epicardial leads , Monaldi Archives for Chest Disease: Early Access
- Nitin Goel, Nitesh Goyal, Ravishankar Nagaraja , Raj Kumar, Systemic corticosteroids for management of ‘long-COVID’: an evaluation after 3 months of treatment , Monaldi Archives for Chest Disease: Vol. 92 No. 2 (2022)
- Zehra Naseem, Muhammad Mussab Khakwani, Maaha Ayub, Ahmed Ayaz, Bushra Jamil, Ainan Arshad, SARS-CoV-2 induced coagulopathy and potential role of anticoagulation: Scoping review of literature , Monaldi Archives for Chest Disease: Vol. 92 No. 4 (2022)
- Stavros Anevlavis, Georgia Karpathiou, Paschalis Ntolios, Marios E. Froudarakis, Two years progression-free survival under vinorelbine metronomic therapy of a patient with metastatic epithelioid hemangioendothelioma , Monaldi Archives for Chest Disease: Vol. 92 No. 4 (2022)
- Cleante Scarduelli, Francesco Inglese, Massimiliano Beccaria, Fabio Spreafico, Martina Garuti, Antonietta Pecoriello, Giulia Cervi, Graziana Greco, Sara Scarduelli, Giuseppe Lucchini, Giuseppe De Donno, Claudio Borghi, Pulmonary embolism in patients with severe COVID-19 treated with intermediate- to full-dose enoxaparin: A retrospective study , Monaldi Archives for Chest Disease: Vol. 91 No. 3 (2021)
- Ignasi Garcia-Olivé, Helena Sintes, Joaquim Radua, Jordi Deportos, Isabel Nogueira, Cristian Morales-Indiano, Jorge Abad Capa, Antoni Rosell, Predicting pulmonary embolism in patients infected with COVID-19 based on D-dimer levels and days between diagnosis of the infection and D-dimer determination , Monaldi Archives for Chest Disease: Vol. 91 No. 2 (2021)
- Grazia Mazzeo, Luigi Aronne, Domenica Francesca Mariniello, Valentino Allocca, Maria Ilaria Palma, Francesco Saverio Cerqua, Carlo Iadevaia, Adriano Costigliola, Roberto Parrella, Andrea Bianco, Vanvitelli/Monaldi COVID Group, Which impact for proton pump inhibitors in SARS-CoV-2 pneumonia , Monaldi Archives for Chest Disease: Vol. 91 No. 4 (2021)
- Maria Vincenza Polito, Mario Ferraioli, Alessandra Nocilla, Guido Coppola, Federica D’Auria, Antonio Marzano, Luca Barnabei, Marisa Malinconico, Eduardo Bossone, Francesco Ferrara, CHARGE syndrome and congenital heart diseases: systematic review of literature , Monaldi Archives for Chest Disease: Vol. 94 No. 3 (2024)
- Carmine Guarino, Cristiano Cesaro, Giuseppe La Cerra, Raffaella Lucci, Flavio Cesaro, Enzo Zamparelli, Gianfranco Gaglione, Agostina Pontarelli, Annunziata De Rosa, Roberto Parrella, Endobronchial hamartoma in a young COVID-19 symptomatic woman. Radical endoscopic treatment with a disposable bronchoscope. Case Report , Monaldi Archives for Chest Disease: Vol. 92 No. 3 (2022)
<< < 44 45 46 47 48 49 50 51 52 53 > >>
You may also start an advanced similarity search for this article.
